RxDoctor Payments Data

Stephanie Cox

Family · Newport News, VANPI 1508510553

Payments from drug & device makers

$4,350in general payments, 2019–2025

Across 221 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$568
  • Lilly USA, LLC$508
  • Novo Nordisk$487
  • Pfizer$401
  • AstraZeneca$389
  • Amgen$321
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,342100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,350 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$83,474
MounjaroTirzepatide22$35,645
EliquisApixaban25$27,592
VraylarCariprazine Hcl12$25,478
RybelsusSemaglutide21$24,729
FarxigaDapagliflozin Propanediol27$21,506
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,209
LinzessLinaclotide13$10,502
Aripiprazole22$1,587
Atorvastatin Calcium159$1,130
Levothyroxine Sodium107$997
Lidocaine12$933
Mirtazapine18$883
Levetiracetam12$787
Memantine Hcl16$741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$487$108,20380 claims
AbbVieVraylar, Linzess$568$35,98125 claims
Lilly USA, LLCMounjaro$508$35,64522 claims
PfizerEliquis$401$27,59225 claims
AstraZenecaFarxiga$389$21,50627 claims
GSKTrelegy Ellipta$254$15,20922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.

Other family in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →